title: [Cost-effectiveness analysis in type 2 diabetes patients without hypertension].
abstract: OBJECTIVE
  To determine SOHDi program cost-effectiveness (S = overweight, O = obesity, H = hypertension, Di = diabetes) in type 2 diabetes patients (DM2) without hypertension.
  
  
  METHODS
  Sample included 32 patients. The effectiveness was measured by the blood glucose values. The SOHDi intervention cost included physician medical attention cost (PMAC), laboratory cost (LC), education group cost and individual evaluation cost. The cost of the traditional alternative medical attention (TAMA) contemplated PMAC and LC. The analysis cost-effectiveness included different intervals measurements, equal or smaller than 140 mg/dL blood glucose levels.
  
  
  RESULTS
  The percentage of population with equal or smaller than 140 mg/dL blood glucose (effectiveness) in SOHDi was 23.3%, in TAMA was 44.8%. The average cost in SOHDi was $2202.22; in TAMA $1930.79. In the cases with blood glucose equal or smaller to 140 mg/dL the cost of effectiveness of 50% was $4726 in SOHDi and $2155 in TAMA. In this same situation the effectiveness by $1000 was 10.58% in SOHDi and 23.20% in TAMA.
  
  
  CONCLUSIONS
  The SOHDi group is not the best alternative, at least not in the present operational conditions.
authors.affiliation: Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Querétaro, México. enrique.villarreal@imss.gob.mx
authors.forename: Enrique
authors.initials: E
authors.lastname: Villarreal-Ríos
authors.forename: Emma Rosa
authors.initials: ER
authors.lastname: Vargas-Daza
authors.forename: Liliana
authors.initials: L
authors.lastname: Galicia-Rodríguez
authors.forename: Lidia
authors.initials: L
authors.lastname: Martínez-González
authors.forename: Claudia
authors.initials: C
authors.lastname: Neri-Calero
authors.forename: María Guadalupe
authors.initials: MG
authors.lastname: Hernández-Centeno
mesh_terms: D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000191:economics* / Q000628:therapy*; D005260:Female; D006801:Humans; D006973:Hypertension; D008297:Male; D008875:Middle Aged